One doctor is losing her lunch over a bizarre ad in the window of a new pizza-bagel joint in Midtown that encourages people ...

Madison Mills examines two trending tickers on the Yahoo Finance platform during Thursday's trading session: UiPath (PATH) stock tumbles double digits after issuing weak guidance as pharmaceutical ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

Novo has expanded its Chicago team and established its presence in New York, Philadelphia, Nashville, Minneapolis, and Dallas. Novo’s new address, 200 W. Madison St., is steps from the city’s iconic ...

Novo Nordisk's (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. Its U.S.-traded American depositary receipts (ADRs) saw their price slump by more than 2% following the ...

Among weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...